We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly, GSK and VIR Antibody Combination Sees Positive Results in Phase 2 Trial
Eli Lilly, GSK and VIR Antibody Combination Sees Positive Results in Phase 2 Trial
Eli Lilly’s bamlanivimab with Vir Biotechnology’s and GlaxoSmithKline’s VIR-7831 appear to be a potent antibody combination against COVID-19 infection, significantly reducing viral load in a mid-stage study.